Diagnosis and risk classification of acute coronary syndrome by means of CT-proET-1 in combination with NT-proBNP

1. A method for the in-vitro diagnosis or prognosis of acute coronary syndrome, or post-myocardial infarction, comprising

determining the level of CT-pro-ET-1 in at least one blood sample from a patient, wherein said CT-pro-ET-1 refers to SEQ ID NO: 2, or SEQ ID NO: 3, or both, and

determining the level of NT-proBNP (SEQ ID NO: 4) in said at least one blood sample from said patient,

wherein an increased level of CT-pro-ET-1 and an increased level of NT-proBNP in said at least one sample indicates the presence in said patient of acute coronary syndrome, or an increased risk of or an unfavorable prognosis of acute coronary syndrome or post-myocardial infarction for said patient.

2. The method for the diagnosis and/or risk classification of acute coronary syndrome, and/or post myocardial infarction according to claim 1 , for identifying patients having an increased risk and/or an unfavorable prognosis of acute coronary syndrome, particularly myocardial infarction, Angina pectoris, and/or post-myocardial infarction.

3. The method for the diagnosis and/or risk classification of acute coronary syndrome, and/or post-myocardial infarction according to claim 1 , wherein the patient is a symptomatic and/or asymptomatic patient, particularly an emergency room patient.

4. The method for the diagnosis and/or risk classification of acute coronary syndrome, and/or post-myocardial infarction according to claim 1 for the therapy control of acute coronary syndrome, particularly myocardial infarction (AMI) and Angina pectoris (AP), and/or post-myocardial infarction, particularly in intensive medicine or emergency medicine.

5. The method for the diagnosis and/or risk classification of acute coronary syndrome, and/or post-myocardial infarction according to claim 1 for carrying out clinical decisions, particularly the continuative treatment and therapy by means of pharmaceuticals, particularly in intensive medicine or emergency medicine, including the decision for hospitalizing the patient.

6. The method for the diagnosis and/or risk classification of acute coronary syndrome, and/or post-myocardial infarction according to claim 1 for the prognosis, for the differential diagnostic early detection and recognition, for the assessment of the degree of severity, and for the therapy-accompanying assessment of the course.

7. The method according to claim 1 , characterized in that the cut-off values are 80-150 pmol/l for CT-proET-1, and 750-1100 pmol/l for NT-proBNP.

8. The method according to claim 1 , characterized in that additionally a determination of at least one further marker is carried out, which is selected from the group of inflammatory markers, cardiovascular markers, neurohormonal markers, or ischemic markers.

9. The method according to claim 8 , characterized in that the inflammatory marker is selected from at least one marker of the group of C-reactive protein (CRP), cytokins, such as TNF-alpha, interleukins, such as IL-6, procalcitonin (1-116, 3-116), and adhesion molecules, such as VCAM or ICAM.

10. The method according to claim 8 , characterized in that the cardiovascular marker is selected from the group of creatine kinasis, myoglobin, myeloperoxidasis, natriuretic protein, particularly ANP (or ANF), proANP, NT-proANP, BNP, pro-BNP, or a partial sequence thereof, cardial roponin, CRP, and circulation regulating (pro)hormones, such as pro-gastrin-releasing peptide (proGRP), pro-endothelin-1, pro-leptin, pro-neuropeptide-Y, pro-somatostatin, pro-neuropeptide-YY, pro-opiomelanocortin, or pro-adrenomedullin (proADM), or a partial sequence thereof.

11. The method according to claim 8 , characterized in that the ischemic marker is selected from at least one marker of the group of troponin I and T, CK-MB.

12. The method according to claim 8 , characterized in that the neurohormonal marker is at least one natriuretic protein, particularly ANP (or ANF), proANP, NT-proANP, BNP, proBNP, or a partial sequence thereof.

13. The method according to claim 1 , characterized in that the parallel or simultaneous determinations of the marker are to be carried out.

14. The method according to claim 1 , characterized in that the determinations are carried out on at least one patient sample.

15. The method according to claim 1 , characterized in that the determinations are carried out on an automatic analysis device, particularly by means of a Kryptor.

16. The method according to claim 1 , characterized in that the determinations are carried out by means of a quick test, particularly in single or multiple parameter determinations.

17. A kit for the risk classification of acute coronary syndrome, myocardial infarction, Angina pectoris, and/or post-myocardial infarction containing detection reagents for determining CT-proET 1, wherein said CT-pro-ET-1 refers to SEQ ID NO: 2, or SEQ ID NO: 3, or both, in combination with NT-proBNP (SEQ ID No. 4) and optionally further markers according to claim 8 , and auxiliary means.

18. A diagnostic device for carrying out a method according to claim 1 .

19. The kit for the diagnosis of acute coronary syndrome, myocardial infarction, and/or Angina pectoris, containing detection reagents for determining CT-proET-1, wherein said CT-pro-ET-1 refers to SEQ ID NO: 2, or SEQ ID NO: 3, or both, in combination with NT-proBNP (SEQ ID No. 4) and optionally further markers according to claim 8 , and auxiliary means.

20. The method according to claim 7 , characterized in that the cut-off values are 90-130 pmol/l for CT-proET-1, and 800-950 pmol/l for NT-proBNP.